Percutaneous microwave ablation versus surgical resection for ovarian cancer liver metastasis

References

• Loizzi V, Rossi C, Cormio G, et al. Clinical features of hepatic metastasis in patients with ovarian cancer. Int J Gynecol Cancer. 2005;15(1):26–31.
   PubMed Web of Science ®Google Scholar
• Tempany CM, Zou KH, Silverman SG, et al. Staging of advanced ovarian cancer: comparison of imaging modalities–report from the Radiological Diagnostic Oncology Group. Radiology. 2000;215(3):761–767.
   PubMed Web of Science ®Google Scholar
• Fischer OJ, Marguerie M, Brotto LA. Sexual function, quality of life, and experiences of women with ovarian cancer: a mixed-methods study. Sex Med. 2019;7(4):530–539.
   PubMed Web of Science ®Google Scholar
• Cormio G, Rossi C, Cazzolla A, et al. Distant metastases in ovarian carcinoma. Int J Gynecol Cancer. 2003;13(2):125–129.
   PubMed Web of Science ®Google Scholar
• Rose PG, Piver MS, Tsukada Y, et al. Metastatic patterns in histologic variants of ovarian cancer. An autopsy study. Cancer. 1989;64(7):1508–1513.
   PubMed Web of Science ®Google Scholar
• Aletti GD, Podratz KC, Cliby WA, et al. Stage IV ovarian cancer: disease site-specific rationale for postoperative treatment. Gynecol Oncol. 2009;112(1):22–27.
   PubMed Web of Science ®Google Scholar
• Liang P, Yu J, Yu XL, et al. Percutaneous cooled-tip microwave ablation under ultrasound guidance for primary liver cancer: a multicentre analysis of 1363 treatment-naive lesions in 1007 patients in China. Gut. 2012;61(7):1100–1101.
   PubMed Web of Science ®Google Scholar
• Bhardwaj N, Strickland AD, Ahmad F, et al. Microwave ablation for unresectable hepatic tumours: clinical results using a novel microwave probe and generator. Eur J Surg Oncol. 2010;36(3):264–268.
   PubMed Web of Science ®Google Scholar
• Yu J, Yu XL, Han ZY, et al. Percutaneous cooled-probe microwave versus radiofrequency ablation in early-stage hepatocellular carcinoma: a phase III randomised controlled trial. Gut. 2017;66(6):1172–1173.
   PubMed Web of Science ®Google Scholar
• Castle SM, Salas N, Leveillee RJ. Initial experience using microwave ablation therapy for renal tumor treatment: 18-month follow-up. Urology. 2011;77(4):792–797.
   PubMed Web of Science ®Google Scholar
• Qi C, Yu XL, Liang P, et al. Ultrasound-guided microwave ablation for abdominal wall metastatic tumors: a preliminary study. WJG. 2012;18(23):3008–3014.
   PubMed Web of Science ®Google Scholar
• Wei Z, Ye X, Yang X, et al. Efficacy and safety of microwave ablation in the treatment of patients with oligometastatic non-small-cell lung cancer: a retrospective study. Int J Hyperthermia. 2019;36(1):827–834.
   PubMed Web of Science ®Google Scholar
• Maciolek KA, Abel EJ, Best SL, et al. Percutaneous microwave ablation for local control of metastatic renal cell carcinoma. Abdom Radiol. 2018;43(9):2446–2454.
   PubMed Web of Science ®Google Scholar
• Liu B, Huang G, Jiang C, et al. Ultrasound-guided percutaneous radiofrequency ablation of liver metastasis from ovarian cancer: a single-center initial experience. Int J Gynecol Cancer. 2017;27(6):1261–1267.
   PubMed Web of Science ®Google Scholar
• Wang M, Zhou J, Zhang L, et al. Surgical treatment of ovarian cancer liver metastasis. Hepatobiliary Surg Nutr. 2019;8(2):129–137.
   PubMed Web of Science ®Google Scholar
• Makuuchi M, Hasegawa H, Yamazaki S. Ultrasonically guided subsegmentectomy. Surg Gynecol Obstet. 1985;161(4):346–350.
   PubMedGoogle Scholar
• Deraco M, Virzì S, Iusco DR, et al. Secondary cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent epithelial ovarian cancer: a multi-institutional study. BJOG. 2012;119(7):800–809.
   PubMed Web of Science ®Google Scholar
• Nagtegaal ID, Odze RD, Klimstra D, The WHO Classification of Tumours Editorial Board, et al. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2019;76(2):182–188.
   PubMed Web of Science ®Google Scholar
• Halkia E, Spiliotis J. The role of cytoreductive surgery and HIPEC in epithelial ovarian cancer. J Buon. 2015;20(Suppl. 1):S12–S28.
   Google Scholar
• Cornberg M, Tacke F, Karlsen TH. Clinical Practice Guidelines of the European Association for the study of the Liver - Advancing methodology but preserving practicability. J Hepatol. 2019;70(1):5–7.
   PubMed Web of Science ®Google Scholar
• Bacalbasa N, Dima S, Brasoveanu V, et al. Liver resection for ovarian cancer liver metastases as part of cytoreductive surgery is safe and may bring survival benefit. World J Surg Onc. 2015;13(1):235.
   PubMedGoogle Scholar
• Gao W, Guo Z, Zhang X, et al. Percutaneous cryoablation of ovarian cancer metastasis to the liver: initial experience in 13 patients. Int J Gynecol Cancer. 2015;25(5):802–808.
   PubMed Web of Science ®Google Scholar
• Liu F, Yu X, Liu Z, et al. Comparison of ultrasound-guided percutaneous microwave ablation and parathyroidectomy for primary hyperparathyroidism. Int J Hyperthermia. 2019;36(1):835–840.
   PubMed Web of Science ®Google Scholar
• Tang X, Ding M, Lu B, et al. Outcomes of ultrasound-guided percutaneous microwave ablation versus surgical resection for symptomatic large hepatic hemangiomas. Int J Hyperthermia. 2019;36(1):632–639.
   PubMed Web of Science ®Google Scholar
• Xu B, Zhou NM, Cao WT, et al. Comparative study on operative trauma between microwave ablation and surgical treatment for papillary thyroid microcarcinoma. World J Clin Cases. 2018;6(15):936–943.
   PubMed Web of Science ®Google Scholar
• Xu C, Li L, Xu W, et al. Ultrasound-guided percutaneous microwave ablation versus surgical resection for recurrent intrahepatic cholangiocarcinoma: intermediate-term results. Int J Hyperthermia. 2019;36(1):351–358.
   PubMed Web of Science ®Google Scholar
• de Lacerda GF, Howlader N, Mariotto AB. Differences in cancer survival with relative versus cause-specific approaches: an update using more accurate life tables. Cancer Epidemiol Biomarkers Prev. 2019;28(9):1544–1551.
   PubMed Web of Science ®Google Scholar
• Salem ME, Yin J, Weinberg BA, et al. Clinicopathological differences and survival outcomes with first-line therapy in patients with left-sided colon cancer and rectal cancer: Pooled analysis of 2879 patients from AGITG (MAX), COIN, FOCUS2, OPUS, CRYSTAL and COIN-B trials in the ARCAD database. Eur J Cancer. 2018;103:205–213.
   PubMed Web of Science ®Google Scholar
• Nicholas MN, Khoja L, Atenafu EG, et al. Prognostic factors for first-line therapy and overall survival of metastatic uveal melanoma: The Princess Margaret Cancer Centre experience. Melanoma Res. 2018;28(6):571–577.
   PubMed Web of Science ®Google Scholar